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PHARMACOLOGICAL IMMUNOSUPPRESSION
A vast range of different compounds seem capable of depressing the immune
response, however, it has been disappointing that so few of these have shown
potential as immunosuppressive agents in man. The action of many has been to
suppress lymphocyte reactivity in vitro and of those that are capable of prolonging
graft survival in animals in addition, just a handful have been found to be safe and
effective in man. It is not intended in this paper to discuss in great detail the
properties of most of these compounds since many excellent reviews already exist,-5
rather I would wish to concentrate on those drugs that have proved useful as
immunosuppressive agents in man.
ANTI-METABOLITES
These compounds interfere with protein synthesis by competing for and blocking
specific receptors. They include the purine antagonist 6-mercaptopurine and
azathioprine, the pyrimidine antagonist 5-fluorouracil, cytosine arabinoside, and
the folic acid antagonist methotrexate. Since these agents are cycle specific and only
effective against proliferating cells, they are most effective when given after, rather
than before, the exposure to antigen.
6-mercaptopurine and azathioprine
6-mercaptopurine is an analogue of the purine base hypoxanthine in which the
6-hydroxil group has been replaced by a thiol group. Azathioprine is the same
compound with an imidazol group attached to the sulphur atom. It is rapidly
converted back into 6-mercaptopurine and other compounds following ingestion
and for this reason the activity of the two compounds are largely the same.
Nonetheless, various differences have been described in the actions of the two
compounds and these have been summarized by Berenbaum.5 During the
breakdown of 6-mercaptopurine thioinosinic acid is produced which competes with
its analogue inosinic acid for the enzyme which converts inosinic acid to xanthylic
acid. This latter step is important in the synthesis of DNA, and its inhibition
profoundly affects RNA synthesis as well. All immune responses requiring cell
proliferation may be inhibited including antibody production, graft rejection and
the induction ofauto-allergic disease. Azathioprine and 6-mercaptopurine also exert
a non-specific anti-inflammatory effect but this is probably not an important part of
its immunosuppressive action. As has been mentioned previously the optimum time
for administering these drugs is after exposure to antigen and it has been shown that
antibody production in man is effected very little if they are given before.6
Nonetheless "pretreatment" with azathioprine has been shown to be effective in
36prolonging renal transplant survival in dogs7 and as a result some transplant centres
elect to start treatment a few days before transplantation in those patients who are
planned to receive a kidney from a living relative. Azathioprine and
6-mercaptopurine have been shown to be capable of prolonging the survival of
organ allografts in many experimental animals 2 although the effect varies
considerably between species. Rats for example are affected very little by these
drugs. Even in human organ transplantation azathioprine is rather ineffective on its
own. It has been the practice in some kidney transplant centres in the past to give
azathioprine alone but graft survival was on the whole rather poor.8 Kreis et al,
described a series of 54 patients in whom only azathioprine was administered after
transplantation.9 Because of a high incidence of early renal failure episodes, 88% of
these patients subsequently received steroids during the first week although not all
these episodes were likely to have been due to rejection. 6-mercaptopurine and
azathioprine exert their main toxic effects on the bone marrow to cause leukopenia,
thrombocytopenia and occasionally anaemia. Approximately 20% of kidney
transplant patients experience leukopenic episodes, the frequency of which are
related to the dose of azathioprine given as well as the degree of function of the
transplant.10 Fortunately the bone marrow usually recovers quickly when the drug is
withdrawn or the dosage reduced. Azathioprine is more toxic when administered
with allopurinol since the degradation of azathioprine is blocked by the drug. Very
occasionally azathioprine can cause liver dysfunction and when this occurs it is
common practice to substitute cyclophosphamide for azathioprine.
Methotrexate
Methotrexate is an analogue of folic acid in which a methyl and amino group
respectively replace a hydrogen atom and a hydroxyl group. It binds to the enzyme
folic reductase which has the effect of blocking the recycling of folic acid
derivatives. Since these derivatives are involved in the conversion ofdeoxyuridine to
thymidine, DNA synthesis and cell proliferation are impaired.
Apart from its immunosuppressive activity, the drug is also an inhibitor of
inflammation1' due to the way it can block responses to histamine and other
mediators of inflammation.
Like azathioprine, methotrexate is active against dividing cells and is more
effective as an immunosuppressant when given shortly after the antigen.'2 Antibody
responses are affected more than cell mediated immunity although methotrexate is
incapable of suppressing responses in previously sensitized individuals.'
The drug has been shown to prolong skin graft survival in some animals but
perhaps because of this rather weak immunosuppressive effect, it has not found a
place in routine immunosuppression in man, although it has been employed in bone
marrow transplantation. Its principal use is in the treatment of cancer when it is
given in a high dose followed by a "folinic acid rescue".
ALKYLATING AGENTS
These compounds possess an alkyl radical with active end groups (usually chlorine
atoms) which can bind to two or more different molecules causing them to become
cross linked. The alkylating agents are mostly cycle specific but their activity is in
37general not confined to just one phase. Some agents, such as nitrogen mustard,
sulpha mustard and cyclophosphamide are also active against resting (Go) cells.
With most alkylating agents DNA synthesis is inhibited to a greater extent than is
RNA synthesis but the alkylation of DNA does not necessarily lead to cell death
since repair is possible. Although alkylating agents have shown to be most useful in
treating malignancies they have been of little value on the whole as immuno-
suppressants.
Cyclophosphamide
Cyclophosphamide is inactive in vitro but is oxydised in the liver into active
metabolites which reach peak serum levels one hour after ingestion. These are
excreted in the urine together with a small amount of unchanged drug. In patients
with severe renal insufficiency, the reduced clearance of the metabolites can cause
increased toxicity. The activation of cyclophosphamide can be slowed ifother drugs
are given which are metabolised through the same pathway, eg. steroids and
barbiturates, although repeated administration of these drugs will have the opposite
effect as the result of enzyme induction.5 By cross linking DNA, cyclophosphamide
interferes with the reproduction of immunologically competent cells and it is most
effective in depressing antibody responses in animals if given 24-48 hours after
immunisation.13 Santos and his colleagues have studied the effects of cyclo-
phosphamide administration in man by challenging patients who were to receive
cyclophosphamide for malignant disease with bacterial antigens.'4 He also found
that antibody responses were best inhibited if cyclophosphamide was given shortly
after the antigen. In this respect cyclophosphamide resembles the antimetabolites.
However, resting cells can also be damaged and small lymphocytes can be killed by a
process unrelated to cell proliferation. Turke and Poulter have suggested that the
drug acts more against B-cells than T-cells (at least in the guinea pig),'5 and this
would explain the proficiency with which cyclophosphamide can suppress antibody
responses in animals. High doses will also suppress cell mediated immunity and
prolonged skin graft survival has been noted when cyclophosphamide has been
administered to mice, rats, guinea pigs and rabbits.2 Under certain defined
conditions, cyclophosphamide can be used to make animals tolerant to a variety of
antigens including allo-antigens but unfortunately these very promising results have
never been reproduced in man. Nonetheless cyclophosphamide is still used to
prepare patients for bone marrow transplantation. In 1971 Starzl proposed that
cyclophosphamide might be substituted for azathioprine with advantage in
cadaveric renal and hepatic transplantation.'6 Patient follow-up was only two to
three months however and there was no comparable control group. The increased
toxicity of cyclophosphamide has probably been responsible for dissuading other
transplant centres from using the drug in this'way. Cyclophosphamide has been
combined with azathioprine and prednisolone in animal experiments and found to
have asuperior immunosuppressive effect thanjust azathioprine and prednisolone.'
Such a combination has been tried in human kidney graft recipients following
transplantation but it is not very effective and undoubtedly toxic.'l.9 Uldall et al,
have used cyclophosphamide for treating chronic steroid resistent rejection with
some benefit although some serious complications were seen.2° Like azathioprine,
cyclophosphamide can cause leukopenia and thrombocytopenia, and haemorrhagic
cystitis, testicular atrophy, nausea and vomiting are other side effects.
38STEROIDS
In organ transplantation, steroids are frequently administered in high
concentrations as a prophylaxis against rejection or for treatment of rejection after
it has occurred. The side effects of such treatment are well documented and it is
therefore surprising that the dosage is still largely empirical with different centres
using very contrasting regimes.2' Although many corticosteroids have been
synthesized, prednisone and prednisolone are the two most commonly used in
transplantation and their actions are comparable. Unlike the antimetabolites,
steroids have a large number of actions at the biochemical level. They bind to
specific cytoplasmic receptors which transport them to intranuclear receptors where,
at toxic levels they inhibit a variety of enzymes with a resulting depression of
protein, RNA and DNA synthesis. There is extensive death of small lymphocytes
both in the blood and in the thymus, lymph nodes and spleen, although the
mechanism for this last effect is not well understood. In some species of animals
steroids are able to suppress antibody production but there is little evidence for this
in man. Cell mediated immunity however is depressed in most species but the
evidence that steroids protect tissue allografts is curiously sparse considering how
essential steroids are in clinical transplantation. It is often assumed that in clinical
transplantation high dose steroid therapy must be started immediately rejection has
been diagnosed if the graft is to be saved, and yet this may not be true. Using a rat
heart allograft model we have found to the contrary that a single pulse of
methylprednisolone is more effective in prolonging graft survival when given late
than when given early in the rejection process.22
It is usual practice to give maintenance doses of steroids from the day of organ
transplantation, increasing the dose whenever rejection is suspected. Traditionally,
steroid therapy is commenced at a high dose (150-250 mg of prednisolone/day)
which is gradually reduced over the following weeks to a maintenance dose of
10-30mg/day. Such high starting doses may be quite unnecessary since excellent
results can be obtained for cadaver kidney transplantation when patients are given
just 20mg of prednisolone/day after grafting.23 A controlled clinical trial comparing
a high and low dose regime has demonstrated no advantage from using the higher
dose.24 Even the large steroid dose that is customarily given on the day of
transplantation seems to be unnecessary.25 Steroids seem to be the only agents which
can reliably reverse rejection episodes. They can be administered to patients as
tablets orally or as an intravenous "bolus" injection. There is some evidence that
intravenous therapy gives fewer complications 26' 27 but this has not been borne out in
clinical trials.28
The numerous toxic effects of steroids have already been eluded to. The stunting
effect of steroids in children may be lessened by administering the drug on alternate
days although the evidence for this is not very convincing.
DRUG TREATMENT OF THE GRAFT DONOR
It has been argued by Guttmann and others that much of the antigenicity of a
transplanted kidney is contributed by a population of "passenger leukocytes" that
inhabit the graft. They have shown, in some elegant experiments, that rat kidney
allografts deprived of their passenger leukocytes are tolerated by the host, and
kidney isografts populated with allogenic leukocytes are "rejected".29, 30 After
39experimenting with many cytotoxic agents they found that high doses of cyclo-
phosphamide and methylprednisolone given to the donor animals five hours before
the removal of the kidney gave the most graft protection. Accordingly they used
such a regime to treat human cadaver (brain dead) kidney donors.3' The dose of
methylprednisolone given was 5g and cyclophosphamide 3g, although this was later
increased to 7g.32 Kidneys from treated donors fared very well with 71%o functioning
one year after transplantation. However, kidneys from non-pretreated donors also
did well in this centre and no attempt was made to compare the two in a controlled
way. Another poorly controlled study was reported by Zincke and Wood33 in which
a similar scheme was used to prepare the donors of kidneys used to transplant 21
recipients. These grafts survived better than did those harvested from two groups of
untreated donors. Such reports caused considerable interest and more controlled
trials ofdonor pretreatment were soon carriedoutinother centres.34-36 Unfortunately
none of these studies were able to confirm these results, and graft survival at one
year in both pretreated and control groups was barely 50% in each ofthe trials. The
value of donor pretreatment in cadaveric renal transplantation therefore remains in
doubt at the present time.
DISCONTINUANCE OF IMMUNOSUPPRESSION
It has been known for many years that kidney transplants will often survive for
many months in dogs and rats following the withdrawal of all immunosuppressive
treatment. Patients with long surviving kidney transplants are frequently maintained
on very small doses of immunosuppressive drugs and it has been debated as to
whether this treatment is really necessary in view of these experimental findings.
Occasionally patients have stopped their own treatment and apparently come to no
harm.3" Owens et al, have reported six patients (five ofwhich had kidney transplants
from living related donors) whose immunosuppression was stopped between 3 and
108 months after transplantation.38 Only two patients subsequently experienced
rejection episodes but one kidney was lost. Similar reports have come from other
transplant centres, 3940 but on the whole most people's experience has been much
less favourable41' 42 and total withdrawal of immunosuppression is not often
attempted. It would appear however that azathioprine can be safely withdrawn two
or more years after transplantation43 and this is sometimes necessary in cases of
bone marrow intolerance. Having successfully withdrawn azathioprine in ten
patients, Naik et al,4" attempted to withdraw prednisolone as well but found that
rejection episodes occurred when the dose went below 7 mg/day. Thus steroids, at
least, are required indefinitely for long term function of renal transplants in man.
CONCLUSIO>N
Pharmacological immunosuppression has been a neglected field for many years.
As the result of the efforts of large pharmaceutical companies, many new and
effective remedies have been introduced for the treatment of infection, malignant
disease, peptic ulcer, etc., but the needs of transplantation have been overlooked.
Many hundreds ofcompounds possess immunosuppressive activity ofsorts but none
has been found until recently to challenge azathioprine and steroids as the basis for
immunosuppression in man. Fortunately recent experimental and clinical studies
with Cyclosporin-A have proved the exception and the use of this and similar
40compounds will undoubtedly lead to an improvement in pharmacological immuno-
suppression in the years ahead.
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